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In the Netherlands, isolation of Mycobacterium xenopi 
is infrequent, and its clinical relevance is often uncertain. 
To determine clinical relevance and determinants, we ret-
rospectively reviewed medical ﬁ   les of all patients in the 
Netherlands in whom M. xenopi was isolated from Janu-
ary 1999 through March 2005 by using diagnostic criteria 
for nontuberculous mycobacterial infection published by the 
American Thoracic Society. We found 49 patients, mostly 
white men, with an average age of 60 years and pre-exist-
ing pulmonary disease; of these patients, 25 (51%) met the 
diagnostic criteria. Mycobacterial genotype, based on 16S 
rRNA gene sequencing, was associated with true infection. 
Most infections were pulmonary, but pleural and spinal in-
fections (spinal in HIV-infected patients) were also noted. 
Treatment regimens varied in content and duration; some 
patients were overtreated and some were undertreated.
M
ycobacterium xenopi was ﬁ  rst described by Schwa-
bacher in 1959; it was isolated from skin lesions in 
a clawed frog and named after the ofﬁ  cial species designa-
tion of the frog, Xenopus laevis (1). Thereafter, these slow-
growing mycobacteria have been recovered from heated 
water systems in many countries and more recently from 
natural waters in Finland (2). Transmission to humans is 
believed to originate from the environment, through aero-
sol inhalation or ingestion. Human-to-human transmission 
and transmission from animal reservoirs remain controver-
sial because these routes have not been proven by molecu-
lar typing (3,4).
Pulmonary  M. xenopi infections are most common, 
but extrapulmonary and disseminated infections have also 
been recorded (5,6). A predisposing factor is impaired im-
munity, either local (e.g., pre-existing pulmonary disease) 
or systemic (e.g., hematologic malignancy, immunosup-
pressive medication, or HIV/AIDS) (5,7).
Its survival in ﬂ  owing water systems and resistance 
to common disinfectants enables M. xenopi to contami-
nate laboratory samples and medical devices such as bron-
choscopes, thus causing healthcare-acquired (pseudo) 
infections and laboratory cross-contaminations (3,6,8,9). 
Differentiating true infection from pseudoinfection is of 
paramount importance because treatment of M. xenopi 
infections is time-consuming and often complicated. The 
British Thoracic Society (BTS) trial in 2001 established 
that treatment for pulmonary infections should consist of 
a 2-year course of rifampin and ethambutol; regimens in-
cluding macrolides or ﬂ  uoroquinolones are still being in-
vestigated (10). The American Thoracic Society (ATS) es-
tablished general criteria for the diagnosis and treatment of 
nontuberculous mycobacterial, not speciﬁ  cally M. xenopi, 
infections. The treatment guidelines are similar to those by 
the BTS, although the ATS guidelines advocate macrolide-
containing regimens (5).
To assess frequency and clinical relevance of M. 
xenopi isolation and its determinants in the Netherlands, 
we performed a retrospective case study. We used the ATS 
diagnostic criteria available during the study period to dif-
ferentiate true infection from pseudoinfection.
Methods
To determine clinical relevance, we examined medical 
records of all patients in the Netherlands from whom M. 
xenopi had been isolated from January 1999 through March 
2005. The following variables were extracted from the re-
cords: sex, age, predisposing factors, symptoms, chest im-
aging results, treatment and outcome, and drug susceptibil-
ity and status according to the ATS diagnostic criteria (5).
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Laboratory diagnosis of the isolates was made by the 
Dutch National Institute of Public Health and the Environ-
ment (RIVM) or by a local hospital laboratory. RIVM acts 
as the national reference laboratory that provides identiﬁ  -
cation, drug-susceptibility testing, and genotyping of my-
cobacterial isolates for all hospitals and other healthcare 
institutions in the Netherlands. To identify a mycobacte-
rial isolate, Hain GenoType MTBC line-blot (Hain Life-
science, Nehren, Germany) was used after PCR-based am-
pliﬁ  cation to determine whether an isolate was a member of 
the M. tuberculosis complex. If the reaction was negative, 
an INNO-LiPA MYCOBACTERIA (Innogenetics, Gent, 
Belgium) reverse hybridization multiple DNA probe assay 
was used to differentiate between the more common spe-
cies of nontuberculous mycobacteria, including M. xenopi 
(11). Before 2004, 16S rRNA gene sequence analysis was 
performed, after ruling out membership in the M. tubercu-
losis complex, by using the AccuProbe MTB DNA probe 
kit (GenProbe, San Diego, CA, USA). The result was com-
pared with the RIVM and BLAST (National Center for 
Biotechnology Information, www.ncbi.nlm.nih.gov) 16S 
rRNA gene sequence databases (12).
On the basis of the results at position 90 in the 151-bp 
hypervariable region of the 16S gene, 2 M. xenopi genotypes 
were discerned; a C at position 90 distinguished M. xenopi 
I and a T distinguished M. xenopi II. Retrospectively, the 
16S rRNA genes of all M. xenopi isolates at RIVM were 
sequenced and assigned to their respective genotypes. 
Susceptibility testing was performed by using an agar 
dilution method (13). Drugs in the susceptibility testing 
panel were isoniazid, rifampin, ethambutol, streptomycin, 
cycloserine, prothionamide, amikacin, ciproﬂ  oxacin, clo-
fazimine, clarithromycin, and rifabutin. The Pearson χ2 test 
was used for statistical correlations. The local ethics com-
mittee approved the study.
Results
We found 49 patients with nontuberculous mycobacte-
rial infection (Table 1); of these, 25 (51%) met the ATS 
diagnostic criteria. Isolates from 46 patients were identiﬁ  ed 
to the genotype level, I or II. Sequencing failed for 2, and 
1 was unavailable at RIVM. M. xenopi I was found for 28 
patients, M. xenopi II for 13, and mixed (types I and II) 
for 5. Isolation of type II was signiﬁ  cantly associated with 
fulﬁ  llment of the ATS criteria compared with isolation of 
type I only (77% vs 39%; odds ratio [OR] 5.1, 95% conﬁ  -
dence interval [CI] 1.2–23.0, p = 0.025). When we deﬁ  ned 
M. xenopi II cultures as “involving M. xenopi II,” and thus 
included the mixed cultures, the correlation increased in 
signiﬁ  cance (OR 5.4, 95% CI 1.4–20.8, p = 0.011).
Clinical signs and symptoms varied widely and were 
not associated with fulﬁ  llment of the ATS diagnostic crite-
ria (Table 1). Chest radiographs were taken for all patients, 
except for 2 who had spinal infection (Table 1). Cavitation 
was the only radiographic ﬁ  nding signiﬁ  cantly associated 
with fulﬁ  llment of the ATS diagnostic criteria (OR 14.3, 
95% CI 2.7–75.6, p = 0.001). Results of additional com-
puted tomography scanning, performed for 27 patients, 
were not associated with fulﬁ  llment of the ATS diagnostic 
criteria (data not shown).
We found 4 cases of extrapulmonary disease, 2 cases 
of pleural M. xenopi infection, and 2 cases of spondylodis-
citis (in HIV–co-infected patients). The pleural infections 
were diagnosed by biopsy of pleural tissue for 1 patient and 
repeated culture of pleural ﬂ  uid for the other, after chest ra-
diograph demonstrated pleural thickening and ﬂ  uid collec-
tion. The spinal infections were diagnosed by bone biopsy. 
In the pleural and bone biopsy specimens, granulomatous 
lesions with central necrosis were observed.
For most patients, M. xenopi was ﬁ  rst isolated from 
sputum (51%), bronchoalveolar lavage ﬂ  uid (35%), or lung 
biopsy sample (4%). Remaining isolates were from bone 
biopsy samples (4%), pleural ﬂ  uid (2%), pleural biopsy 
samples (2%), and stool samples (2%). Acid-fast bacilli 
were detected with direct microscopy of primary samples 
for 39% of patients. An acid-fast bacilli–positive primary 
sample, regardless of its nature, was signiﬁ  cantly associ-
ated with fulﬁ  llment of the ATS diagnostic criteria (OR 
8.2, 95% CI 2.1–31.6, p<0.001).
Treatment was started for 25 of 49 patients, of whom 
19 met the ATS diagnostic criteria. Therapy consisted of 
medication for 21 patients, surgery for 2, or both for 2. 
Surgery consisted of lobectomy, pulmonary wedge resec-
tion, Clagett pleurostomy, and vertebral surgery with psoas 
muscle abscess drainage. Medication regimens varied 
widely but generally included rifampin, isoniazid, etham-
butol, clarithromycin, ciproﬂ  oxacin, and pyrazinamide in 
various 3- to 4-drug combinations. Duration of therapy var-
ied between 5 days and 2.5 years, with a mean duration of 
9 months. Macrolides were included in regimens for 58% 
and quinolones for 37% of the patients who met the ATS 
diagnostic criteria and received drug treatment.
Antimycobacterial treatment cured 11 (58%) patients 
who met the ATS diagnostic criteria: 7 with M. xenopi II, 2 
with M. xenopi I, and 2 with M. xenopi I and II. We deﬁ  ned 
cure as resolution of symptoms and negative cultures after 
ﬁ  nishing treatment, until the end of our study period (range 
0–60 months, median 25 months). Treatment failure, de-
ﬁ  ned as protracted culture positivity for M. xenopi during 
and after adequate treatment, was noted for 4 (21%). Four 
other patients died. Treatment failure or death was not as-
sociated with genotype, susceptibility pattern, predisposing 
conditions, or radiographic imaging results.
Although they fulﬁ  lled the ATS diagnostic criteria, 4 
patients did not receive treatment. Of these, 1 recovered 
spontaneously; 2 remained positive for acid-fast bacilli, 
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culture, or both throughout the study period; and 1 died. 
These outcomes were not associated with speciﬁ  c geno-
types or patient factors.
Susceptibility testing was performed for 47 isolates 
from 42 patients. For 5 patients, cultures failed to grow for 
testing; for 2 others, cultures were not available. Results 
for isoniazid, rifampin, and ethambutol are shown in Table 
2. Isolates were susceptible to all other compounds tested. 
Susceptibility testing of follow-up cultures was performed 
for 5 patients. M. xenopi bacteria in 2 patients treated with 
rifampin became resistant to rifampin and to ethambutol 
in 1 patient. For 9 patients, susceptibility testing results 
inﬂ  uenced the treatment regimens, mostly by inclusion or 
exclusion of rifampin and ethambutol or by adding a quino-
lone or macrolide agent.
For 6 patients with cavitation visible on chest radio-
graph, of whom 4 met the ATS diagnostic criteria, fungi 
were cultured simultaneously (Aspergillus fumigatus from 
4, A. ﬂ  avus from 1, and Scedosporium apiospermum from 
1). Antifungal treatment was initiated for 4 patients, which 
meant true nontuberculous mycobacteria infection was left 
untreated for 2.
Four patients who had received antimycobacterial 
treatment for M. xenopi infection before (mean duration 8 
months) had relapses; the mean interval between discontin-
uation of drug treatment and relapse was 28 months (range 
12–39). We found no evidence of geographic clustering, 
which suggests nosocomial transmission or a pseudo-out-
break. The number of new isolates per year remained steady 
at ≈8 per year. At least 5 patients were treated in preven-
tive isolation for 2–15 days until M. tuberculosis complex 
infection was excluded by PCR.
Discussion
Clinical relevance of M. xenopi isolation, deﬁ  ned by ful-
ﬁ  llment of the ATS diagnostic criteria, was likely in 51% of 
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Table 1. Baseline population characteristics of 49 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 
through March 2005* 
Characteristic ATS+ (n = 25) ATS– (n = 24) Total (%)
Demographics 
 Male  sex 19 18 37 (76)
 Mean  age,  y 60 60 60
 Dutch  origin 24 20 44 (90)
Concurrent and predisposing conditions 
  Pre-existing pulmonary disease 21 18 39 (80)
  Chronic obstructive pulmonary disease  17 14 31 (63)
 Lung  cancer 1 3 4 (8)
 Prior  tuberculosis 0 2 2 (4)
 Recurrent  pulmonary  infection† 5 2 7 (14)
 Bronchiectasis 2 4 6 (12)
 Smoker,  current/  past 15/ 6 11/ 3 35 (71)
 Alcohol  abuse 2 3 5 (10)
  High-dose steroid use‡ 3 5 8 (16)
 HIV  infection 2 5 7 (14)
  Mean CD4 count in HIV-infected patients, cells/mL  226 126 159
 Hematologic  malignancy 0 1 1 (2)
  Otherwise impaired immunity§ 2 1 3 (6)
Signs and symptoms 
 Productive  cough 21 20 41 (84)
 Hemoptysis 5 4 9 (18)
 Dyspnea 14 9 23 (47)
 Fever 11 6 17 (35)
 Weight  loss 12 7 19 (39)
 Malaise 16 10 26 (53)
Chest radiographic abnormalities 
 Infiltrate 15 12 27 (55)
 Cavity 12¶ 3 15 (31)
 Pleural  thickening 3 4 7 (14)
 Emphysema 9 9 18 (37)
 Space-occupying  lesion 1 3 4 (8)
*ATS+, American Thoracic Society diagnostic criteria for nontuberculous mycobacterial infection met; ATS–, ATS diagnostic criteria for nontuberculous 
mycobacterial infection not met. 
†>3 requiring treatment in 6 months before primary Mycobacteria xenopi culture. 
‡>15 mg prednisone/day for >3 months before primary M. xenopi culture. 
§Diabetes mellitus, cisplatinum chemotherapy, anorexia nervosa (all n = 1). 
¶Significant association (odds ratio 14.3, 95% confidence interval 2.7–75.6, p = 0.001). RESEARCH
patients; mycobacterial genotype II was a major determinant. 
To our knowledge, this phenomenon and its causal mecha-
nisms have not been described. If further evidence emerges, 
16S rRNA gene sequencing may become a relevant addition 
to the diagnostic algorithm of M. xenopi infection.
The ATS diagnostic criteria are designed for M. avium, 
M. kansasii, and M. abscessus infections, although the au-
thors state “there is no reason to believe these criteria would 
not be applicable to other species” (5). Because the BTS 
statement focuses on management rather than speciﬁ  c diag-
nostic criteria (14), the ATS diagnostic criteria are recom-
mended for the clinical setting. Of the main ATS diagnostic 
components, 2 were each signiﬁ  cantly associated with true 
infection in our study (cavitary lesions on chest radiograph 
and acid-fast bacilli on primary samples), thereby support-
ing the ATS criteria.
The ATS diagnostic criteria, however, have 1 limita-
tion. Patients with pre-existing cavitary lesions are likely to 
have respiratory symptoms; they meet the radiologic crite-
ria and are more likely to harbor mycobacteria in the cavity, 
which are not necessarily responsible for their symptoms 
and cavity formation. Cavity characteristics cannot reliably 
predict the cavity’s origin or pathogenesis (15). The uncer-
tainty is compounded when fungi are cultured simultane-
ously, which suggests matching requirements for in vivo 
success of these microorganisms or selective impaired im-
munity. Determining which organism causes disease in the 
patient is difﬁ  cult.
The undertreatment and overtreatment that we noted 
indicates a relative lack of knowledge in physicians, main-
ly those specializing in pulmonary conditions, concerning 
nontuberculous mycobacteria infections. Unnecessary drug 
treatment could harm the patient in terms of adverse effects 
and costs (16), and undertreatment of patients who fulﬁ  ll 
the diagnostic criteria is potentially harmful to the patients’ 
health.
The baseline characteristics of our study group are 
similar to those in studies of nontuberculous mycobacte-
ria patients in societies with low HIV prevalence (5,10). 
The North American series included more HIV-infected 
patients, which lowered the mean age of patients in these 
studies (17,18). Pre-existing pulmonary diseases are major 
predisposing factors and may be causally associated with 
isolation of M. xenopi. However, M. xenopi may have been 
isolated more often because physicians were more focused 
on mycobacterial cultures for this category of patients. 
Minor predisposing factors were HIV infection or oth-
er causes of impaired immunity, which, in addition to the 
causal relationship, probably reﬂ  ect the low prevalence of 
HIV infection compared with chronic pulmonary disease in 
the Netherlands. Also, because most HIV-infected patients 
receive highly active antiretroviral therapy, fewer cases of 
severe HIV immunosuppression and its co-infections are 
seen. HIV infection predisposes patients to extrapulmo-
nary M. xenopi infection, especially spinal infection (6,19). 
Those with HIV-associated spinal M. xenopi infection had 
rising CD4 counts after starting or changing highly active 
antiretroviral therapy regimens (Table 1). Possibly, their 
M. xenopi infection was an expression of immune reconsti-
tution inﬂ  ammatory syndrome (20). We found no previous 
reports of pleural infections.
Although the treatment regimens recorded in our study 
were not in accordance with the current standards of the BTS 
(14) and ATS (5), cure rates were high. Although partly the 
result of the restricted deﬁ  nition of “cure” resulting from 
our research methods, this ﬁ  nding does bring the validity of 
the ATS diagnostic criteria into question. Despite meeting 
these criteria, some patients might have cleared M. xenopi 
infection without treatment. This possibility is endorsed 
by the spontaneous recovery of a minority of patients who 
met the ATS criteria but were not treated. Alternatively, 
the regimen of 24 months of rifampin and ethambutol ad-
vised by the BTS may not be better than similar regimens 
of shorter duration. The addition of macrolides and quino-
lones to therapy regimens might also account for the high 
cure rates after relatively short treatment durations.
Susceptibility testing results were similar to those pub-
lished previously (21), but their value in clinical practice is 
uncertain. Interpretation of the laboratory results is difﬁ  cult 
because of discrepancies between in vitro susceptibility 
and in vivo response to treatment (5,21). In our study, re-
sults rarely inﬂ  uenced treatment regimens; when they did, 
choice of regimen was controversial and not in accordance 
with ATS and BTS guidelines (5,14). Increasing use of 
PCR to rule out M. tuberculosis infection can be valuable 
for preventing or shortening patient isolation.
In conclusion, clinical isolation of M. xenopi was rel-
evant for 51% of the patients; mycobacterial genotype was 
a major determinant. Currently, the ATS diagnostic crite-
ria are the best tool for determining clinical relevance. We 
strongly recommend increased awareness of these diagnos-
tic criteria and management guidelines by ATS and BTS. 
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Table 2. Baseline in vitro susceptibility of 47 primary isolates from 42 patients with nontuberculous mycobacterial infection, the
Netherlands, January 1999 through March 2005
Drug, no. (%), MIC
Susceptibility  Isoniazid Rifampin Ethambutol
Susceptible 9 (21), MIC 0.2 mg/L 29 (69), MIC <1mg/L 5 (12), MIC 5 mg/L
Intermediate 32 (76), MIC 0.5–1.0 mg/L 11 (26), MIC 10 mg/L
Resistant 1 (2), MIC >1 mg/L 13 (31), MIC >1 mg/L 26 (62), MIC >10 mg/LMycobacterium xenopi, the Netherlands
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